Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCropper (J) Regulatory News (CRPR)

Share Price Information for Cropper (J) (CRPR)

Share Price is delayed by 15 minutes
Get Live Data
365.00    20.00 (5.80%)
Bid:
350.00
Ask:
380.00
Spread: 30.00 (8.571%)
Market Cap: £34.88m
CRPR Live PriceLast checked at - London Stock Exchange

Intraday Cropper (J) Share Chart

Trading Update

8 Mar 2021 07:00

RNS Number : 4015R
Cropper(James) PLC
08 March 2021
 

Cropper(James) PLC

 

8 March 2021

James Cropper plc ("James Cropper" or the "Company")

Trading update

 

James Cropper PLC, the advanced materials and paper products group, is pleased to issue a positive trading update for the 52 weeks to 27 March 2021.

As reported in the half year results to 26 September 2020, the first half of the year had been particularly challenging due to the significant impact of the Covid-19 pandemic. The Group responded quickly to the challenges taking swift action to protect staff, reduce costs, optimise cash flow and protect liquidity. All divisions of the Group were affected to varying degrees by the pandemic. Since the half year, trading has improved, and the restructuring program is now complete.

In January 2021, the TFP division acquired PV3 Technologies Limited, a company specialising in the development and manufacture of electrochemical materials used in the creation of hydrogen. The acquisition is the latest step in TFP's growth plans, providing the opportunity to further enhance TFP's market position in the hydrogen economy. Following the suspension of all major capital expenditure in H1 due to the pandemic, work on installing the additional production line has now recommenced and is expected to be complete in summer of 2021.

Colourform's rate of growth has been impacted by a pandemic related downturn within the beauty and spirit sectors. Nonetheless, it is expected that revenues will be up on the previous year.

The Paper division endured the biggest impact from the pandemic as a result of global lockdowns affecting demand for luxury packaging, education and event collateral. In the first half, revenues were 45% down, compared to the comparable period last year, with the reduced demand leading to periods of inefficient or no production. Revenues in H2 have improved but expected to be 20% down compared to the comparable period last year.

The Company acted promptly at the start of the pandemic to conserve cash and implement immediate savings. It has good headroom against all its banking covenants and is in a strong financial position with liquidity of over £18 million from cash, overdraft and other available facilities including a £4m loan from the Coronavirus Large Business Interruption Loan Scheme. This is expected to be sufficient for the Company to return to more normal trading conditions, to invest and to emerge from the pandemic stronger.

Due to the improving trading performance and continued operational focus the Board expects the results for the year ending 27 March 2021 to be improved from previous expectations. The profit for the year ending 27 March 2021, before exceptional costs, is expected to be above £3.5m on sales of around £77m. This is an improvement from previous market expectations and includes around £2.9m of the Coronavirus Job Retention Scheme and Paycheck Protection Program government schemes.

This announcement contains information that would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

 

 

For further enquiries, please contact:

James Cropper PLC (AIM: CRPR)

Phil Wild, CEO

Isabelle Maddock, CFO

Tel: +44 (0) 1539 722002

www.jamescropper.com

 

 

Shore Capital

Robert Finlay, Henry Willcocks

John More

Tel: + 44 (0) 207 408 4050

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDKPBDCBKDCNK
Date   Source Headline
14th Apr 20267:00 amRNSFull Year Trading Update
27th Mar 20262:50 pmRNSDirector/PDMR Shareholding
10th Mar 20267:00 amRNS-RCollaboration with Hexcel on Composite Recycling
5th Dec 20259:34 amRNSHolding(s) in Company
2nd Dec 20257:00 amRNSPCA Shareholdings
17th Nov 20257:00 amRNSInterim Results
5th Nov 20257:00 amRNSNotice of Results and Investor Presentation
20th Oct 20257:00 amRNSCorrection: PDMR and PCA Shareholdings
17th Oct 20254:12 pmRNSPDMR and PCA Shareholdings
15th Sep 20257:00 amRNSDirector/PDMR Shareholding
3rd Sep 20253:34 pmRNSResult of AGM
3rd Sep 20257:00 amRNSAGM Trading Update
7th Aug 20257:00 amRNSNotice of Annual General Meeting
4th Aug 20257:00 amRNSGrant of Awards under Long-Term Incentive Plan
17th Jul 20257:00 amRNSFull Year Results
15th Jul 20257:00 amRNSNotice of Full Year Results
7th Jul 20257:00 amRNSTrading and Paper & Packaging Customer Update
23rd Jun 20257:00 amRNS-RRecording of Capital Markets Event Presentation
18th Jun 20257:00 amRNSStrategy Update and Capital Markets Event
9th Jun 20257:00 amRNSRevised Terms Agreed for UK Banking Facility
5th Jun 20257:00 amRNS-RNotice of Capital Markets Event
19th May 20257:00 amRNSDirector/PDMR Shareholding
12th May 20257:00 amRNSDirector/PDMR Shareholding
7th May 20257:00 amRNSFull Year Trading Update
1st May 20259:14 amRNS€1.75m sale of non-core IP assets
1st Apr 20257:00 amRNS-RStrategic Collaboration with HOERBIGER
14th Feb 20253:32 pmRNSDirector/PDMR Shareholding
3rd Feb 20257:00 amRNSPDMR and PCA Shareholding
30th Jan 20257:00 amRNSConfirmation of Chief Executive Officer Succession
7th Jan 20257:00 amRNSDirectorate Change
23rd Dec 20249:21 amRNSDirector/PDMR Shareholding
20th Nov 20247:00 amRNSInterim Results
4th Nov 202412:03 pmRNSNotification of Major Holdings
1st Nov 20241:05 pmRNSNotice of Interim Results
29th Oct 20247:00 amRNSChief Executive Officer Succession
10th Oct 202410:14 amRNSDirector/PDMR Shareholding
8th Oct 20244:39 pmRNSDirector/PDMR Shareholding
10th Sep 20243:19 pmRNSGrant of Awards under Long-Term Incentive Plan
4th Sep 20244:32 pmRNSResult of Annual General Meeting
4th Sep 20247:00 amRNSAGM Trading Update
5th Aug 202411:56 amRNSNotice of Annual General Meeting
23rd Jul 20247:00 amRNSFull Year Results
22nd Jul 20249:43 amRNSDirectorate Changes
10th Jul 20247:00 amRNSNotice of Full Year Results
14th Jun 202411:00 amRNSAgreement of Bank Covenant Amendments
23rd May 20247:00 amRNSAppointment of MD, Advanced Materials
30th Apr 20247:00 amRNSFull Year Trading Update
12th Mar 20243:06 pmRNSDirector/PDMR Shareholding
8th Mar 20242:25 pmRNSDirector/PDMR Shareholding
17th Jan 20247:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.